Table 4.
Time to resolution and distribution of screening examination modality, age, screening mammography result, and cancer stage at diagnosis for common work-up pathways ending in biopsy.
| Mammography, Biopsy | Mammography, Ultrasound, Biopsy | Mammography, Ultrasound, Biopsy, Biopsy | Mammography, Mammography, Ultrasound, Biopsy | Ultrasound, Biopsy | |
|---|---|---|---|---|---|
| Median (IQR*) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | |
| Time to resolution (days) | 15 (9, 24) | 20 (13, 30) | 13 (7, 22) | 16.5 (13, 24.5) | 14 (7, 27) |
| N (%) | N (%) | N (%) | N (%) | N (%) | |
| Modality of screening examination | |||||
| Digital | 1100 (51.3) | 979 (61.3) | 123 (24.5) | 11 (3.2) | 115 (38.6) |
| Screen-film | 1045 (48.7) | 617 (38.7) | 379 (75.5) | 335 (96.8) | 183 (61.4) |
| Age (years) | |||||
| 40–49 | 498 (23.2) | 541 (33.9) | 100 (19.9) | 119 (34.4) | 101 (33.9) |
| 50–59 | 780 (36.4) | 515 (32.3) | 185 (36.9) | 108 (31.2) | 93 (31.2) |
| 60–69 | 491 (22.9) | 309 (19.4) | 125 (24.9) | 64 (18.5) | 64 (21.5) |
| 70–79 | 253 (11.8) | 161 (10.1) | 76 (15.1) | 47 (13.6) | 27 (9.1) |
| 80–89 | 123 (5.7) | 70 (4.4) | 16 (3.2) | 8 (2.3) | 13 (4.4) |
| Result | |||||
| False-positive | 1888 (88.0) | 1114 (69.8) | 470 (93.6) | 240 (69.4) | 268 (89.9) |
| True-positive | 257 (12.0) | 482 (30.2) | 32 (6.4) | 106 (30.6) | 30 (10.1) |
| Cancer stage at diagnosis† | |||||
| Stage 0 | 182 (70.8) | 63 (13.1) | 6 (18.8) | 17 (16.0) | 0 (0) |
| Stage I | 52 (20.2) | 287 (59.5) | 15 (46.9) | 54 (50.9) | 17 (56.7) |
| Stage IIa | 9 (3.5) | 86 (17.8) | 3 (9.4) | 19 (17.9) | 4 (13.3) |
| Stage IIb | 2 (0.8) | 14 (2.9) | 4 (12.5) | 3 (2.8) | 6 (20.0) |
| Stage III | 7 (2.7) | 18 (3.7) | 2 (6.2) | 9 (8.5) | 3 (10.0) |
| Stage IV | 0 (0) | 2 (0.4) | 0 (0) | 0 (0) | 0 (0) |
| Unknown | 5 (1.9) | 12 (2.5) | 2 (6.2) | 4 (3.8) | 0 (0) |
*
IQR = Interquartile range
†
Proportions for cancer stage at diagnosis computed from among women with a cancer diagnosis within one year of the screening mammogram